Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Pilon Fractures: Challenges and Solutions.

Saad BN, Yingling JM, Liporace FA, Yoon RS.

Orthop Res Rev. 2019 Sep 24;11:149-157. doi: 10.2147/ORR.S170956. eCollection 2019.

2.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE.

Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23.

3.

A rare case of Candida parapsilosis osteomyelitis: a literature review and proposed treatment algorithm.

Yingling JM, Sun L, Yoon R, Liporace F.

Patient Saf Surg. 2017 Dec 21;11:31. doi: 10.1186/s13037-017-0146-9. eCollection 2017.

4.

Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.

Sturdivant JM, Royalty SM, Lin CW, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA.

Bioorg Med Chem Lett. 2016 May 15;26(10):2475-2480. doi: 10.1016/j.bmcl.2016.03.104. Epub 2016 Apr 1.

PMID:
27072905
5.

Outcomes associated with common and immigrant-group-specific responses to intimate terrorism.

Yingling J, Morash M, Song J.

Violence Against Women. 2015 Feb;21(2):206-28. doi: 10.1177/1077801214564769. Epub 2014 Dec 24.

PMID:
25540250
6.

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.

Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM.

Br J Clin Pharmacol. 2014 May;77(5):796-807.

7.

Marriage migration, patriarchal bargains, and wife abuse: a study of South Asian women.

Chaudhuri S, Morash M, Yingling J.

Violence Against Women. 2014 Feb;20(2):141-61. doi: 10.1177/1077801214521326. Epub 2014 Feb 3.

PMID:
24493153
8.

Test-retest reliability for aerodynamic measures of voice.

Awan SN, Novaleski CK, Yingling JR.

J Voice. 2013 Nov;27(6):674-84. doi: 10.1016/j.jvoice.2013.07.002. Epub 2013 Oct 8.

PMID:
24119644
9.

LIS1 controls mitosis and mitotic spindle organization via the LIS1-NDEL1-dynein complex.

Moon HM, Youn YH, Pemble H, Yingling J, Wittmann T, Wynshaw-Boris A.

Hum Mol Genet. 2014 Jan 15;23(2):449-66. doi: 10.1093/hmg/ddt436. Epub 2013 Sep 12.

10.

LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.

Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Gröne HJ, Yingling J, Lahn M, Wirkner U, Huber PE.

Clin Cancer Res. 2012 Jul 1;18(13):3616-27. doi: 10.1158/1078-0432.CCR-11-2855. Epub 2012 Apr 30.

11.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM.

Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.

12.

Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ.

Cancer Res. 2011 Mar 15;71(6):2339-49. doi: 10.1158/0008-5472.CAN-10-2941. Epub 2011 Jan 31.

13.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR.

Cancer Res. 2011 Mar 1;71(5):1849-57. doi: 10.1158/0008-5472.CAN-10-3298. Epub 2011 Jan 13.

14.

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A.

Cancer Res. 2011 Feb 1;71(3):955-63. doi: 10.1158/0008-5472.CAN-10-2933. Epub 2010 Dec 28. Erratum in: Cancer Res. 2011 Apr 1;71(7):2806. Mantzaris, Giannis [corrected to Mantzaris, Ioannis].

15.

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.

Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J.

Cancer Cell. 2010 Dec 14;18(6):655-68. doi: 10.1016/j.ccr.2010.10.023.

16.

Converging technologies to enable induced pluripotent stem cells in drug discovery.

Flynn P, Yingling J, Shoemaker D.

Regen Med. 2010 Jul;5(4):489-91. doi: 10.2217/rme.10.48. No abstract available.

17.

Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M.

Mol Cancer. 2010 May 26;9:122. doi: 10.1186/1476-4598-9-122.

18.

Smad7 regulates the adult neural stem/progenitor cell pool in a transforming growth factor beta- and bone morphogenetic protein-independent manner.

Krampert M, Chirasani SR, Wachs FP, Aigner R, Bogdahn U, Yingling JM, Heldin CH, Aigner L, Heuchel R.

Mol Cell Biol. 2010 Jul;30(14):3685-94. doi: 10.1128/MCB.00434-09. Epub 2010 May 17.

19.

The prevalence of horizontal violence in New York State registered nurses.

Sellers K, Millenbach L, Kovach N, Yingling JK.

J N Y State Nurses Assoc. 2009 Fall-2010 Winter;40(2):20-5.

PMID:
20415270
20.

Novel embryonic neuronal migration and proliferation defects in Dcx mutant mice are exacerbated by Lis1 reduction.

Pramparo T, Youn YH, Yingling J, Hirotsune S, Wynshaw-Boris A.

J Neurosci. 2010 Feb 24;30(8):3002-12. doi: 10.1523/JNEUROSCI.4851-09.2010.

21.

Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.

O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M.

Biologics. 2008 Sep;2(3):563-9.

22.

Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model.

Chen Y, Wei T, Yan L, Lawrence F, Qian HR, Burkholder TP, Starling JJ, Yingling JM, Shou J.

BMC Genomics. 2008 Jun 2;9:264. doi: 10.1186/1471-2164-9-264.

23.

Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype.

Bharathy S, Xie W, Yingling JM, Reiss M.

Cancer Res. 2008 Mar 15;68(6):1656-66. doi: 10.1158/0008-5472.CAN-07-5089.

24.

Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS.

J Med Chem. 2008 Apr 10;51(7):2302-6. doi: 10.1021/jm701199p. Epub 2008 Mar 4.

PMID:
18314943
25.

TGF-beta signalling-related markers in cancer patients with bone metastasis.

Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M.

Biomarkers. 2008 Mar;13(2):217-36. doi: 10.1080/13547500701676019 .

PMID:
18270872
26.

Neuroepithelial stem cell proliferation requires LIS1 for precise spindle orientation and symmetric division.

Yingling J, Youn YH, Darling D, Toyo-Oka K, Pramparo T, Hirotsune S, Wynshaw-Boris A.

Cell. 2008 Feb 8;132(3):474-86. doi: 10.1016/j.cell.2008.01.026.

27.

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.

Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF.

Eur J Cancer. 2008 Jan;44(1):142-50. Epub 2007 Nov 26.

PMID:
18039567
28.

Analysis of pathway activity in primary tumors and NCI60 cell lines using gene expression profiling data.

Feng XD, Huang SG, Shou JY, Liao BR, Yingling JM, Ye X, Lin X, Gelbert LM, Su EW, Onyia JE, Li SY.

Genomics Proteomics Bioinformatics. 2007 Feb;5(1):15-24.

29.

A failure to communicate: let's get real about improving communication at the end of life.

Yingling J, Keeley M.

Am J Hosp Palliat Care. 2007 Apr-May;24(2):95-7. No abstract available.

PMID:
17502432
30.

Development and validation of a phosphorylated SMAD ex vivo stimulation assay.

Farrington DL, Yingling JM, Fill JA, Yan L, Qian YW, Shou J, Wang X, Ehsani ME, Cleverly AL, Daly TM, Lahn M, Konrad RJ, Ray CA.

Biomarkers. 2007 May-Jun;12(3):313-30.

PMID:
17453744
31.

Assay optimization: a statistical design of experiments approach.

Altekar M, Homon CA, Kashem MA, Mason SW, Nelson RM, Patnaude LA, Yingling J, Taylor PB.

Clin Lab Med. 2007 Mar;27(1):139-54.

PMID:
17416307
32.

Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.

Kashem MA, Nelson RM, Yingling JD, Pullen SS, Prokopowicz AS 3rd, Jones JW, Wolak JP, Rogers GR, Morelock MM, Snow RJ, Homon CA, Jakes S.

J Biomol Screen. 2007 Feb;12(1):70-83. Epub 2006 Dec 8.

PMID:
17166826
33.
34.

Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.

Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA, Beauchamp RD.

J Biol Chem. 2006 Nov 10;281(45):33971-81. Epub 2006 Sep 7.

35.

Satisfaction with primary health care received by families of children with developmental disabilities.

Liptak GS, Orlando M, Yingling JT, Theurer-Kaufman KL, Malay DP, Tompkins LA, Flynn JR.

J Pediatr Health Care. 2006 Jul-Aug;20(4):245-52.

PMID:
16831632
36.

Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

Li HY, Wang Y, Heap CR, King CH, Mundla SR, Voss M, Clawson DK, Yan L, Campbell RM, Anderson BD, Wagner JR, Britt K, Lu KX, McMillen WT, Yingling JM.

J Med Chem. 2006 Mar 23;49(6):2138-42.

PMID:
16539403
37.

Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.

Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL.

Oncogene. 2006 Jun 8;25(24):3408-23. Epub 2005 Sep 26.

PMID:
16186809
38.

Role of 14-3-3 proteins in eukaryotic signaling and development.

Darling DL, Yingling J, Wynshaw-Boris A.

Curr Top Dev Biol. 2005;68:281-315. Review.

PMID:
16125003
39.

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.

Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM.

Biochemistry. 2005 Feb 22;44(7):2293-304.

PMID:
15709742
40.

Development of TGF-beta signalling inhibitors for cancer therapy.

Yingling JM, Blanchard KL, Sawyer JS.

Nat Rev Drug Discov. 2004 Dec;3(12):1011-22. Review.

PMID:
15573100
41.

Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).

Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM.

Curr Opin Drug Discov Devel. 2004 Jul;7(4):437-45. Review.

PMID:
15338953
42.

Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.

Li HY, Wang Y, Yan L, Campbell RM, Anderson BD, Wagner JR, Yingling JM.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3585-8.

PMID:
15177480
43.

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3581-4.

PMID:
15177479
44.

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM.

J Med Chem. 2003 Sep 11;46(19):3953-6.

PMID:
12954047
45.

Miller-Dieker syndrome: analysis of a human contiguous gene syndrome in the mouse.

Yingling J, Toyo-Oka K, Wynshaw-Boris A.

Am J Hum Genet. 2003 Sep;73(3):475-88. Epub 2003 Aug 5. Review. No abstract available.

46.

Multiple dose-dependent effects of Lis1 on cerebral cortical development.

Gambello MJ, Darling DL, Yingling J, Tanaka T, Gleeson JG, Wynshaw-Boris A.

J Neurosci. 2003 Mar 1;23(5):1719-29.

47.

Verbal responses of children and their supportive providers in a pediatric oncology unit.

Yingling J.

J Health Commun. 2000 Oct-Dec;5(4):371-7. No abstract available.

PMID:
11191019
48.

A LIS1/NUDEL/cytoplasmic dynein heavy chain complex in the developing and adult nervous system.

Sasaki S, Shionoya A, Ishida M, Gambello MJ, Yingling J, Wynshaw-Boris A, Hirotsune S.

Neuron. 2000 Dec;28(3):681-96.

49.

A combination assay for simultaneous assessment of multiple signaling pathways.

Goetz AS, Liacos J, Yingling J, Ignar DM.

J Pharmacol Toxicol Methods. 1999 Dec;42(4):225-35.

PMID:
11033438
50.

Competence in language at 24 months: relations with attachment security and home stimulation.

Murray AD, Yingling JL.

J Genet Psychol. 2000 Jun;161(2):133-40.

PMID:
10851676

Supplemental Content

Loading ...
Support Center